151 related articles for article (PubMed ID: 8875209)
21. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
22. Combined androgen blockade.
Crawford ED
Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
[TBL] [Abstract][Full Text] [Related]
23. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
24. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Small EJ; Srinivas S
Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
[TBL] [Abstract][Full Text] [Related]
25. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G
J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657
[TBL] [Abstract][Full Text] [Related]
26. Hormonal treatment of prostate cancer.
Garnick MB
N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
[No Abstract] [Full Text] [Related]
27. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
28. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.
Vailancourt L; Ttu B; Fradet Y; Dupont A; Gomez J; Cusan L; Suburu ER; Diamond P; Candas B; Labrie F
Am J Surg Pathol; 1996 Jan; 20(1):86-93. PubMed ID: 8540613
[TBL] [Abstract][Full Text] [Related]
29. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Labrie F; Candas B; Gomez JL; Cusan L
Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
Têtu B
Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
[No Abstract] [Full Text] [Related]
31. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
32. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Balaji KC; Rabbani F; Tsai H; Bastar A; Fair WR
J Urol; 1999 Sep; 162(3 Pt 1):753-7. PubMed ID: 10458359
[TBL] [Abstract][Full Text] [Related]
33. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
34. Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
Newton M; Kosier JH
Urol Nurs; 1998 Mar; 18(1):56-7, 83. PubMed ID: 9582897
[No Abstract] [Full Text] [Related]
35. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
37. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
38. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
39. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
40. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
Letsch M; Schally AV; Stangelberger A; Groot K; Varga JL
Eur J Cancer; 2004 Feb; 40(3):436-44. PubMed ID: 14746863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
